Singapore’s Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca’s Beyfortus (nirsevimab) for the prevention ...

Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public ...

The Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca's BEYFORTUS (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and ...

BEYFORTUS maintained a favorable safety profile, consistent with clinical study results. [2], [3] About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's ...

Big shakeups may be coming to the childhood vaccination schedule. Here's a look at some of the shots that could be subject to ...

ACOG released updated clinical guidance on vaccination for COVID-19, respiratory syncytial virus and influenza during ...

Coupled with headwinds in China, Merck is also seeing lower demand for Gardasil in Japan. Sales are expected to remain weak in Japan in the second half of 2025. Our estimates for Gardasil sales ...

Respiratory syncytial virus is a common respiratory virus which is most severe in young babies and older adults ...

Ontario is expanding its publicly funded Respiratory Syncytial Virus (RSV) immunization program to cover everyone aged 75 and older, a move the ...